Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These ...

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet." May 22, 2025 Cigna to ...

Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with ... patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not ...